Analysts: Lululemon Should Beat Estimates and 3 More Research Notes to Look Into
Lululemon Athletica (NASDAQ:LULU): William Blair expects lululemon to meet or beat its Q1 earnings estimate of $0.30, the higher end of the company’s guidance. Channel checks indicated that traffic trends remianed healthy throughout Q1 during the black luon recall. Blair keeps an Outperform rating on the shares.
Monster Beverage (NASDAQ:MNST): Stifel maintains that Monster’s sales growth is poised to accelerate, after the company’s announcement that its gross sales rose 9 percent in April and May. The firm keeps a $62 price target and Buy rating on the shares.
Priceline.com (NASDAQ:PCLN): Due to increased confidence in Bookings.com U.S. market share gains, Macquarie has raised its estimates on the company. Shares are Outperform rated, now with a $915 price target, up from $845.
Onyx Pharmaceuticals (NASDAQ:ONXX): JMP Securities recommends buying shares of Onyx on weakness, after reviewing additional data on the efficacy of Onyx’s KMP as a multiple myeloma treatment. The firm remains upbeat on the drug’s outlook and keeps an Outperform rating on the shares.
Don’t Miss: Gun Control: Which Side Has More Passion?